©2016 All Rights Reserved.
Arkana Laboratories is a registered trademark.
Privacy and Terms
Fibrillary GN is a disease undergoing rapid change. In just ten years several clinical disease state associations have been defined, a new treatment paradigm has emerged, new diagnostic tests on renal biopsy have been discovered, and the beginnings of the molecular pathogenesis of the disease have been found. In the coming years, I hope continued research will help us answer a few important questions. First, no controlled, large scale, collaborative trials exist that prove treatment superiority in this disease and are sorely needed. Next, I hope that the discovery of DNAJB9 as a biomarker of this disease ignites a flurry...